Listed

CytomX Therapeutics, Inc.: Form 10-K/A for the period ended Dec 31, 2021

Filed with the SEC on Mar 27, 2023 and accepted by EDGAR at Mar 27, 2023, 16:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-10-01 to 2021-12-31$11.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue12 months2021-01-01 to 2021-12-31$37.3mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2021-10-01 to 2021-12-31$36.6mus-gaap:ResearchAndDevelopmentExpense
Research and development12 months2021-01-01 to 2021-12-31$114.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-10-01 to 2021-12-31−$34.9mus-gaap:OperatingIncomeLoss
Operating income12 months2021-01-01 to 2021-12-31−$116.0mus-gaap:OperatingIncomeLoss
Income tax12 months2021-01-01 to 2021-12-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-10-01 to 2021-12-31−$34.8mus-gaap:NetIncomeLoss
Net income12 months2021-01-01 to 2021-12-31−$115.9mus-gaap:NetIncomeLoss
Diluted shares (weighted)3 months2021-10-01 to 2021-12-3165,295,995 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)12 months2021-01-01 to 2021-12-3164,146,848 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2021-01-01 to 2021-12-31−$119.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2021-01-01 to 2021-12-31$1.6mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-12-31$205.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-12-31$310.3mus-gaap:AssetsCurrent
Total assetsAt period end2021-12-31$339.4mus-gaap:Assets
Current liabilitiesAt period end2021-12-31$77.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-12-31$339.9mus-gaap:Liabilities
Shareholders' equityAt period end2021-12-31−$459.0kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-23-009984. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.